Incanthera plc is a United Kingdom-based specialist oncology company focused on transforming cancer treatment. The Company’s lead product and focus is Sol, a topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company’s products include EP0015, Equin and Duo-C. EP0015 targets the treatment of adult solid cancers remains palliative rather than curative and represents a unmet need. Equin is a quinone-based prodrug activated by the enzyme DT-diaphorase (DTD) which itself is over-expressed in many solid tumours, including breast, colon, liver, bladder, stomach, the central nervous system (CNS), lung tumours and in melanomas. Duo-C focuses upon targeting colorectal cancer using duocarmycins, which are recognized for their extreme cytotoxicity, converted to a prodrug and designed to overcome their intrinsic toxicity and make them manageable and useful in the clinical set up.